Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
What's your choice of next line therapy for a metastatic papillary RCC who has progressed on cabozantinib?
Answer from: Medical Oncologist at Community Practice
Combination immunotherapy works well.
Sign in or Register to read more
15923
Related Questions
Do you routinely continue patients on anti-PD(L)-1 beyond 2 years of treatment while on IO/TKI for metastatic ccRCC?
When do you start ADT for a patient with a new diagnosis of node positive prostate cancer receiving radiation?
Is there any evidence that ivermectin suppresses the PSA level in prostate cancer?
If a patient diagnosed with seminoma after orchiectomy has margin positive disease noted in the spermatic cord and no overt metastasis on imaging and normal tumor markers, how should this patient be staged?
Are patients with MIBC and bladder neck involvement good candidates for bladder preservation with chemoradiation after maximal, but not complete, TURBT?
For patients with oligo-progressive prostate cancer fit for metastasis-directed therapy but ineligible for radiotherapy or surgery, how do you decide between the types of ablation available?
Is there any evidence for amyloid/amyloidosis causing a spurious/false PSA reading?
What is your preferred choice of therapy for first-line treatment of a patient with good, intermediate, or poor risk stage III nonseminomatous germ cell tumor if the patient is truly cisplatin-ineligible?
What is your experience with Pylarify vs. Posluma PSMA PET for prostate cancer and is one preferred over the other?
How do you reconcile discordant PSMA and MRI findings in patients undergoing definitive radiotherapy for prostate cancer?